To drive future growth, the drugmaker is leaning on newer products including Leqembi, postpartum depression drug Zurzuvae and the rare disease treatments acquired through its $6.5 billion buyout of Reata. "We now have the elements to grow sustainably so our focus is no longer on doing anything of significance in M&A at least for the time being," CEO Christopher Viehbacher said on a media call. Viehbacker said Biogen plans to "branch out" more into immunology and rare disease treatments by invest
To drive future growth, the drugmaker is leaning on newer products including Leqembi, postpartum depression drug Zurzuvae and the rare disease treatments acquired through its $6.5 billion buyout of Reata. "We now have the elements to grow sustainably so our focus is no longer on doing anything of significance in M&A at least for the time being," CEO Christopher Viehbacher said on a media call. Viehbacker said Biogen plans to "branch out" more into immunology and rare disease treatments by investing in research as well as through collaborations.
Eating 80 percent of your daily calorie intake before 1 p.m. could help prevent Type 2 diabetes (T2D), according to a new study. Findings of the study were presented on June 15 at ENDO 2023, the [.]
A panel of independent advisors to the Food and Drug Administration (FDA) has thrown its support behind a new preventive antibody treatment for respiratory syncytial virus (RSV) in newborns and [.]
When doctors first started using hydroxychloroquine (HCQ) to treat covid-19 patients, there was a coordinated effort by Big Media, Big Tech, academia, and the federal government to shut those [.]